Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction

Advances in Urology

Volumn , Issue , 2009, Pages

  Mousa, Shaker A ^a   Tran, Khanh ^a   Levin, Robert M ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 73449085553     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2009/345324     Document Type: Review

References (101)

1. Hellstrom L., Ekelund P., Milsom I., Mellstrom D., The prevalenc of urinary incontinence and use of incontinence aids in 85-year-old men and women Age and Ageing 1990 19 6 383 389
2. Brown J. S., Seeley D. G., Fong J., Black D. M., Ensrud K. E., Grady D., Urinary incontinence in older women: who is at risk? Obstetrics and Gynecology 1996 87 5, part 1 715 721
3. Lagace E. A., Hansen W., Hickner J. M., Prevalence and severity of urinary incontinence in ambulatory adults: an UPRNet study Journal of Family Practice 1993 36 6 610 614
4. Ouslander J. G., Kane R. L., Abrass I. B., Urinary incontinence in elderly nursing home patients Journal of the American Medical Association 1982 248 10 1194 1198
5. Wilson L., Brown J. S., Shin G. P., Luc K. O., Subak L. L., Annual direct cost of urinary incontinence Obstetrics and Gynecology 2001 98 3 398 406
6. Brown J. S., Vittinghoff E., Wyman J. F., Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group Journal of the American Geriatrics Society 2000 48 7 721 725
7. Dmochowski R. R., Sand P. K., Zinner N. R., Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence Urology 2003 62 2 237 242
8. Fantl J. A., Newman D. K., Colling J., Urinary Incontinence in Adults: Acute and Chronic Management 1996 Rockville, Md, USA Agency for Health Care Policy and Research Clinical Practice Guideline no. 2. AHCPR publication no. 96-0682
9. Thom D., Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type Journal of the American Geriatrics Society 1998 46 4 473 480
10. Burgio K. L., Matthews K. A., Engel B. T., Prevalence, incidence and correlates of urinary incontinence in healthy, middle-aged women Journal of Urology 1991 146 5 1255 1259
11. Hu T. W., Wagner T. H., Bentkover J. D., Leblanc K., Zhou S. Z., Hunt T., Costs of urinary incontinence and overactive bladder in the United States: a comparative study Urology 2004 63 3 461 465
12. Homma Y., Paick J. S., Lee J. G., Kawabe K., Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial BJU International 2003 92 7 741 747
13. Kelleher C. J., Cardozo L. D., Khullar V., Salvatore S., A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance British Journal of Obstetrics and Gynaecology 1997 104 9 988 993
14. Hashim H., Abrams P., Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations Drugs 2004 64 15 1643 1656
15. Anderson K. E., Potential benefic of Muscarinic M3 receptor selectivity European Urology Supplements 2002 1 4 23 28
16. Hesch K., Agents for treatment of overactive bladder: a therapeutic class review Baylor University Medical Center Proceedings 2007 20 3 307 314
17. Duckett J. R. A., Hall S., Woodward A., A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance British Journal of Obstetrics and Gynaecology 1998 105 12 1337
18. Hampel C., Wienhold D., Benken N., Eggersmann C., Throff J. W., Definition of overactive bladder and epidemiology of urinary incontinence Urology 1997 50 6, supplement 1 4 14
19. Couture J. A., Valiquette L., Urinary incontinence Annals of Pharmacotherapy 2000 34 5 646 655
20. Gormley E. A., Biofeedback and behavioral therapy for the management of female urinary incontinence Urologic Clinics of North America 2002 29 3 551 557
21. Milne J. L., Moore K. N., Factors impacting self-care for urinary incontinence Urologic Nursing 2006 26 1 41 51
22. Marcell D., Ransel S., Schiau M., Duffy E. G., Treatment option alleviates female urge incontinence The Nurse Practitioner 2003 28 48 54
23. Stewart W. F., Van Rooyen J. B., Cundiff G. W., Prevalence and burden of overactive bladder in the United States World Journal of Urology 2003 20 6 327 336
24. Vapnek J. M., Urinary incontinence: screening and treatment of urinary dysfunction Geriatrics 2001 56 10 25 29
25. OConor R. M., Johannesson M., Hass S. L., Kobelt-Nguyen G., Urge incontinence: quality of life and patients valuation of symptom reduction PharmacoEconomics 1998 14 5 531 539
26. Van Kerrebroeck P., Kreder K., Jonas U., Zinner N., Wein A., Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder Urology 2001 57 3 414 421 (Pubitemid 32192963)
27. Harvey M. A., Baker K., Wells G. A., Tolterodine vs. oxybutynin in the treatment of urge UI: a meta-analysis American Journal of Obstetrics Gynecology 2001 185 56 61
28. Dallosso H. M., Matthews R. J., McGrother C. W., Donaldson M. M. K., Shaw C., The association of diet and other lifestyle factors with the onset of overactive bladder: a longitudinal study in men Public Health Nutrition 2004 7 7 885 891
29. Subak L. L., Whitcomb E., Shen H., Saxton J., Vittinghoff E., Brown J. S., Weight loss: a novel and effective treatment for urinary incontinence Journal of Urology 2005 174 1 190 195
30. Dickson M. J., Nonsurgical treatment of stress urinary incontinence BJOG 2008 115 8 1062 1063
31. Milne J. L., Behavioral therapies for overactive bladder: making sense of the evidence Journal of Wound, Ostomy and Continence Nursing 2008 35 1 93 101
32. Arya L. A., Myers D. L., Jackson N. D., Dietary caffeine intake and the risk for detrusor instability: a case-control study Obstetrics and Gynecology 2000 96 1 85 89
33. Swithinbank L., Hashim H., Abrams P., The effect of fluid intake on urinary symptoms in women Journal of Urology 2005 174 1 187 189
34. Shafik A., Shafik I. A., Overactive bladder inhibition in response to pelvic floor muscle exercises World Journal of Urology 2003 20 6 374 377
35. B K., Berghmans L. C. M., Nonpharmacologic treatments for overactive bladderpelvic floor exercises Urology 2000 55 5, supplement 1 7 11
36. Nygaard I. E., Kreder K. J., Lepic M. M., Fountain K. A., Rhomberg A. T., Efficacy of pelvic floor muscle exercises in women with stress, urge, and mixed urinary incontinence American Journal of Obstetrics and Gynecology 1996 174 1, part 1 120 125
37. Fantl J. A., Wyman J. F., McClish D. K., Efficacy of bladder training in older women with urinary incontinence Journal of the American Medical Association 1991 265 5 609 613
38. Subak L. L., Quesenberry C. P. Jr., Posner S. F., Cattolica E., Soghikian K., The effect of behavioral therapy on urinary incontinence: a randomized controlled trial Obstetrics and Gynecology 2002 100 1 72 78
39. McClish D. K., Fantl J. A., Wyman J. F., Pisani G., Bump R. C., Bladder training in older women with urinary incontinence: relationship between outcome and changes in urodynamic observations Obstetrics and Gynecology 1991 77 2 281 286
40. Elser D. M., Wyman J. F., McClish D. K., The effect of bladder training, pelvic floor muscle training, or combination training on urodynamic parameters in women with urinary incontinence Neurourology and Urodynamics 1999 18 5 427 436
41. Salvatore S., Serati M., Bolis P., Tolterodine for the treatment of overactive bladder Expert Opinion on Pharmacotherapy 2008 9 7 1249 1255
42. Andersson K. E., The overactive bladder: pharmacologic basis of drug treatment Urology 1997 50 6A, supplement 74 79
43. Jonas U., Hfner K., Madersbacher H., Holmdahl T. H., Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group World Journal of Urology 1997 15 2 144 151
44. Millard R., Tuttle J., Moore K., Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity Journal of Urology 1999 161 5 1551 1555
45. Appell R. A., Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis Urology 1997 50 6, supplement 1 90 99
46. Kobelt G., Economic considerations and outcome measurement in urge incontinence Urology 1997 50 6, supplement 1 100 107
47. Nabi G., Cody J. D., Ellis G., Herbison P., Hay-Smith J., Anticholinergic drugs versus placebo for overactive bladder syndrome in adults Cochrane Database of Systematic Reviews 2006 4
48. Waldeck K., Larson B., Andersson K. E., Comparison of oxybutynin and its active metabolite, N-desmethyl-oxybutynin, in the human detrusor and parotid gland The Journal of Urology 1997 157 1093 1097
49. Hughes K. M., Lang J. C. T., Lazare R., Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers Xenobiotica 1992 22 7 859 869
50. Hughes K. M., Lang J. C. T., Lazare R., Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers Xenobiotica 1992 22 7 859 869
51. Nilvebrant L., Sparf B., Dicyclomine, benzhexol, and oxybutynine distinguish between subclasses of muscarinic binding sites European Journal of Pharmacology 1986 123 1 133 143
52. Sthrer M., Mrtz G., Kramer G., Schnabel F., Arnold E. P., Wyndaele J.-J., Propiverine compared to oxybutynin in neurogenic detrusor overactivityresults of a randomized, double-blind, multicenter clinical study European Urology 2007 51 1 235 242
53. OLeary M., Erickson J. R., Smith C. P., McDermott C., Horton J., Chancellor M. B., Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury Journal of Spinal Cord Medicine 2003 26 2 159 162
54. Gleason D. M., Susset J., White C., Munoz D. R., Sand P. K., Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group Urology 1999 54 3 420 423
55. Bennett N., OLeary M., Patel A. S., Xavier M., Erickson J. R., Chancellor M. B., Can higher doses of oxybutynin improve efficacy in neurogenic bladder? Journal of Urology 2004 171 2, part 1 749 751
56. Kay G., Kardiasmenos K., Crook T., Differential effects of the antimuscarinic agents tolterodine tartarate ER and oxybutynin chloride ER on recent momory in older subjects Proceedings of the Annual Meeting of the International Continence Society 2006 Christchurch, New Zealand
57. Kennelly M. K., Lemack G., Foote J., Trop C., Transdermal-oxybutynin improves continence and urodynamics in neurogenic bladder after spinal cord injury The Journal of Spinal Cord Medicine 2007 30 395
58. Dmochowski R. R., Sand P. K., Zinner N. R., Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence Urology 2003 62 237 242
59. Salvatore S., Serati M., Bolis P., Tolterodine for the treatment of overactive bladder Expert Opinion on Pharmacotherapy 2008 9 7 1249 1255
60. Nilvebrant L., Andersson K.-E., Gillberg P.-G., Stahl M., Sparf B., Tolterodinea new bladder-selective antimuscarinic agent European Journal of Pharmacology 1997 327 2-3 195 207
61. Choo M.-S., Doo C. K., Lee K.-S., Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study) International Journal of Clinical Practice 2008 62 2 191 196
62. Nilvebrant L., Halln B., Larsson G., Tolterodinea new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data Life Sciences 1997 60 13-14 1129 1136
63. Swift S., Garely A., Dimpfl T., Payne C., A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder International Urogynecology Journal and Pelvic Floor Dysfunction 2003 14 1 50 55
64. Van Kerrebroeck P., Kreder K., Jonas U., Zinner N., Wein A., Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder Urology 2001 57 3 414 421 (Pubitemid 32192963)
65. Diokno A. C., Appell R. A., Sand P. K., Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial Mayo Clinic Proceedings 2003 78 6 687 695
66. Appell R. A., Sand P., Dmochowski R., Anderson R., Zinner N., Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study Mayo Clinic Proceedings 2001 76 4 358 363
67. Sussman D., Garely A., Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the Antimuscarinic Clinical Effectiveness Trial (ACET) Current Medical Research and Opinion 2002 18 4 177 184
68. Rentzhog L., Stanton S. L., Cardozo L., Nelson E., Fall M., Abrams P., Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study British Journal of Urology 1998 81 1 42 48
69. Abrams P., Freeman R., Anderstrom C., Mattiasson A., Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder British Journal of Urology 1998 81 6 801 810
70. Schladitz-Keil G., Spahn H., Mutschler E., Determination of bioavailability of the quaternary ammonium compound trospium chloride in man from urinary excretion data Arzneimittel Forschung 1986 36 984 987
71. Staskin D., Sand P., Zinner N., Dmochowski R., Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial Journal of Urology 2007 178 3 978 984
72. Fsgen I., Hauri D., Trospium chloride: an effective option for medical treatment of bladder over-activity International Journal of Clinical Pharmacology and Therapeutic Toxicology 2000 38 223 234
73. Horstmann M., Schaefer T., Aguilar Y., Stenzl A., Sievert K. D., Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage Neurourology and Urodynamics 2006 25 5 441 445
74. Stohrere M., Bauer P., Giannetti B. M., Effect of trospium chloride on urodynamic parameter in patients with detrusor hyperreflexia due to spinal cord injuries. A multicenter placebo-controlled double-blind trial Urologia Internationalis 1991 47 138 143
75. Cardozo L., Chapple C. R., Toozs-Hobson P., Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial BJU International 2000 85 6 659 664
76. Menarini M., Del Popolo G., Di Benedetto P., Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? International Journal of Clinical Pharmacology and Therapeutics 2006 44 12 623 632
77. Madersbacher H., Stoher M., Richter R., Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyperreflexia British Journal of Urology 1995 75 452 456
78. Alabaster V. A., Discovery and development of selective M3 antagonists for clinical use Life Sciences 1997 60 13-14 1053 1060
79. Chapple C. R., Cardozo L., Steers W. D., Govier F. E., Solifenacin significantly improves all symptoms of overactive bladder syndrome International Journal of Clinical Practice 2006 60 8 959 966
80. Chapple C. R., Martinez-Garcia R., Selvaggi L., A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial European Urology 2005 48 3 464 470
81. Cardozo L., Lisec M., Millard R., Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder Journal of Urology 2004 172 5, part 1 1919 1924
82. Cardozo L., Hessdorfer E., Milani R., Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial BJU International 2008 102 9 1120 1127
83. Kay G., Crook T., Rekeda L., Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects European Urology 2006 50 2 317 326
84. Michel M. C., de la Rosette J. J. M. C. H., Role of muscarinic receptor antagonists in urgency and nocturia BJU International 2005 96 supplement 1 37 42
85. Guay D. R. P., Clinical pharmacokinetics of drugs used to treat urge incontinence Clinical Pharmacokinetics 2003 42 14 1243 1285
86. Zinner N., Kobashi K. C., Ebinger U., Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy International Journal of Clinical Practice 2008 62 11 1664 1674
87. Solifenacin and darifenacin for overactive bladder Obstetrics Gynecology 2005 106 2 401 402
88. Haab F., Stewart L., Dwyer P., Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder European Urology 2004 45 4 420 429
89. Chapple C. R., Darifenacin is well tolerated and provide significant improvement in the symptoms of overactive bladder: a pooled analysis of phase III studies The Journal of Urology 2004 171, supplement 130. abstract no. 487
90. Wagg A., Wyndaele J. J., Sieber P., Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis The American Journal of Geriatric Pharmacotherapy 2006 4 1 14 24
91. Chancellor M. B., de Miguel F., Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential Geriatrics 2007 62 5 15 24
92. Chapple C. R., Abrams P., Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow European Urology 2005 48 1 102 109
93. Hill S., Elhilali M., Millard R. J., Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study Current Medical Research and Opinion 2007 23 11 2697 2704
94. Foote J., Glavind K., Kralidis G., Wyndaele J.-J., Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist European Urology 2005 48 3 471 477
95. Anderson K. E., Antimuscarinics for treatment of over-active bladder The Lancet Neurology 2004 3 1 46 53
96. Goode P. S., Burgio K. L., Locher J. L., Umlauf M. G., Lloyd L. K., Roth D. L., Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women Journal of the American Geriatrics Society 2002 50 5 808 816
97. Mattiasson A., Blaakaer J., Hoye K., Wein A. J., Simplified bladder training augments the effectiveness of tolterodine in patients with an over-active bladder British Journal of Urology International 2003 91 154 160
98. Burgio K. L., Goode P. S., Locher J. L., Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial Journal of the American Medical Association 2002 288 18 2293 2299
99. Haab F., Corcos J., Siami P., Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study BJU International 2006 98 5 1025 1032
100. Wyman J. F., Fantl J. A., McClish D. K., Bump R. C., Comparative efficacy of behavioral interventions in the management of female urinary incontinence American Journal of Obstetrics and Gynecology 1998 179 4 999 1007
101. Klutke C. G., Burgio K. L., Wyman J. F., Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication Journal of Urology 2009 181 6 2599 2607